Brief: Rani Therapeutics Announces Preclinical Data Demonstrating Successful Oral Delivery Of Semaglutide Via Ranipill HC
05/02/2025 21:18
Feb 5 (Reuters) - Rani Therapeutics Holdings Inc
RANI.O :
* RANI THERAPEUTICS ANNOUNCES PRECLINICAL DATA DEMONSTRATING
SUCCESSFUL ORAL DELIVERY OF SEMAGLUTIDE VIA RANIPILL® HC
* RANI THERAPEUTICS HOLDINGS INC - RT-116 WELL TOLERATED
WITH NO
SERIOUS ADVERSE EVENTS
* RANI THERAPEUTICS HOLDINGS INC - PHASE 1 STUDY FOR RT-114
EXPECTED TO INITIATE IN 2025
Source text: ID:nGNX3fYhzr
Further company coverage: RANI.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Rani Therapeutics Holdings
See all newsRani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Brief: Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Pegbio Co Enters MoU With Rani Therapeutics
Brief: Rani Therapeutics Announces R&D Collaboration With PegBio
Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition